Growing Demand for Cutting-edge Therapeutic Treatments for Retinal Diseases to Aid Market Growth

Degenerative retinal diseases are one of the major causes of irreversible vision loss across the world. Multiple studies pertaining to retinal disorders have revealed that diabetic retinopathy and age-related degeneration (AMD) accounts for over 80% of the reported cases of bilateral blindness worldwide. According to the National Eye Institute of the U.S., nearly 7.7 million individuals suffer from diabetic retinopathy across the U.S. and the number is estimated to reach around 11.3 million by 2030. On a global scale, nearly 36 million individuals suffer from complete vision loss and in most cases, the blindness stems from a range of retinal disorders.

The prevalence of retinal disorders is notably higher in low to medium income countries wherein access to efficient and effective healthcare is a major issue. While developed countries, such as the U.S., Canada, Germany, and the U.K., among others, have laid down the groundwork to address retinal disorders, developing countries continue to make gradual improvements in that regard. Within the retinal disorders treatment market, research and development activities have gained significant momentum, especially over the last decade. Due to the growing demand for cutting-edge retinal disorders treatment and noteworthy investments in research, the retinal disorder treatment market is expected to reach a value of ~US$ 17.6 Bn by the end of 2027.

retinal disorder treatment market infographic

To know the scope of our report Get a Sample on Point-of-Care Retinal Disorder Treatment Market

Progress in Ophthalmic Drug Development to Offer Better Results

In recent times, the development and discovery of new ophthalmic drugs has gained significant momentum. Within the retinal disorders treatment market, drug manufacturers are shifting from traditional drug formulations toward the discovery of new and improved drugs to treat a range of retinal disorders. This factor, along with notable progress in genetic sequencing and molecular biology has paved the way for improved retinal disorders treatment.

Get a glimpse of the in-depth analysis through our Report Brochure

Government, as well as several nonprofit organizations, are increasingly spending on the development of new retinal disorders treatment. Within the retinal disorders treatment market, collaborations between nonprofit organizations and the government are on the rise particularly in developed regions such as North America. For instance, The Foundation Fighting Blindness, a nonprofit organization, is aiding in research pertaining to ophthalmic drug development by funding over 90 researchers around the world. The research activities are largely focusing on the development of new drugs to treat retinal disorders, including inherited retinal degenerative diseases and age-related macular degeneration diseases. Moreover, swift and cost-efficient genetic testing is likely to offer lucrative opportunities for drug developers in the retinal disorder treatment market during the forecast period. Within the retinal disorders treatment market, macular degeneration and diabetic retinopathy disease indication segments are expected to collectively account for over 85% of the total market share, in terms of value– a major factor why researches and studies pertaining to retinal disorders are largely focusing on these disease indications. The macular degeneration disease indication segment is expected to reach a market value of ~US$ 5.3 Bn by 2020 from ~US$ 5.1 Bn in 2019.

Preference for Anti-vascular Endothelial Growth Factor Agents to Remain High

Age-related macular degeneration (AMD), diabetic retinopathy, inherited retinal dystrophies, and diabetic macular degeneration diseases are some of the major retinal disorders that require efficient, reliable, and cost-effective retinal disorder treatments. The advent of anti-vascular endothelial growth factor (VEGF) agents has redefined retinal disorder treatments, such as neovascular (wet) AMD and diabetic macular edema, among others. The adoption of anti-VEGF injections in the retinal disorder treatment market is expected to scale new heights, as these injections have, repeatedly, proved their efficacy in providing relief from a range of retinal disorders. Despite ongoing research pertaining to alternative drug delivery techniques and drugs, anti-VEGF agents therapeutic class segment is expected to account for a share of over 88% of the retinal disorder treatment market during the forecast period. Anti-VEGF agents segment is likely to reach a market value of ~9.4 Bn by 2020.

retinal disorder treatment market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

The retinal disorder treatment market is expected to grow at an impressive CAGR of ~8% during the forecast period. Strides taken by genetic sequencing and molecular biology have paved the way for the development of a range of retinal disorders treatment in recent times. Moreover, research and development activities funded by governments as well as nonprofit organizations pertaining to the development of novel therapeutic strategies for retinal treatment will provide a significant impetus for growth of the retinal disorder treatment market during the forecast period. North America and Europe are expected to be at the helm, in terms of innovation, owing to robust healthcare systems and favorable government policies.

Retinal Disorder Treatment Market: Overview

  • Retinal disorder includes macular degeneration, diabetic retinopathy, diabetic macular edema, and retinal vein occlusion. Age-related macular degeneration is a condition that affects the part of retina responsible for sharp central vision. Two forms of AMD are dry and wet.
  • In case of diabetic retinopathy, retina blood vessels can break down, leak, or get blocked, affecting and impairing vision over time. Nearly half of all people with diabetes are likely to develop some degree of diabetic retinopathy during their lifetime and the risk increases with age and duration of diabetes.
  • Other retinal disorders include macular edema, retinitis pigmentosa, retinoblastoma, macular pucker, and retinal detachment
  • Anti-VEGF agents are used to treat AMD. The leading products under this segment are F. Hoffmann-La Roche Ltd.’s Lucentis and Regeneron Pharmaceuticals, Inc.’s Eylea.
  • Rise in prevalence of retinal disorders due to increase in geriatric patient population is projected to boost the growth of the retinal disorder treatment market. Age-related macular degeneration (AMD) is the leading cause of irreversible blindness around the globe, affecting approximately 196 million by 2020 and increase to 288 million by 2040 globally. Prevalence estimates are on late AMD, involving neovascular AMD and geographic atrophy. In the U.S, the number of patients suffering from AMD is 11 million. This number is expected to double to nearly 22 million by 2050.
  • Age is a prominent risk factor for macular degeneration. The risk of getting advanced age-related macular degeneration increases from 2% for those aging 50 to 59, to nearly 30% for those over the age of 75.
  • Strong product pipeline is also likely to drive the market. In September 2019, Allergan received biologics license application from USFDA for abicipar pegol in the treatment of wet age-related macular degeneration. 

Market Segmentation: Retinal Disorder Treatment Market

  • Based on disease indication, the retinal disorder treatment market has been divided into macular degeneration (dry macular degeneration and wet macular degeneration), diabetic retinopathy, diabetic macular edema, and others (retinal vein occlusion, etc.)
  • In terms of therapeutic class, the retinal disorder treatment market has been classified into anti-VEGF agents and others (anti-inflammatory drugs, etc.)
  • Based on dosage form, the retinal disorder treatment market has been divided into gels, eye solutions, capsules & tablets, eye drops, and ointments
  • In terms of distribution channel, the retinal disorder treatment market has been categorized into hospital pharmacies, retail pharmacies, and online sales
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The report provides current and future revenue (US$ Mn) for each of these segments from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2019 to 2027, along with market size estimations. 

Geographic Overview: Retinal Disorder Treatment Market

  • In terms of region, the retinal disorder treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • The current and future market value in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report from 2017 to 2027, with their CAGRs from 2019 to 2027
  • The study also offers a list of recommendations, highlights, and useful insights of the market which would help new companies willing to enter the market and existing companies to increase market shares, and help in the decision-making process.

Major Players

  • The report concludes with the company profiles section that includes key information about the major players in the market
  • Leading players analyzed in the report include
    • Santen Pharmaceutical Co., Ltd.
    • Regeneron Pharmaceuticals, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • Allergan plc
    • Shire (Takeda Pharmaceutical Company Limited)
    • Bayer AG
    • Graybug Vision, Inc.
    • Novartis AG
    • Acucela Inc. (Kubota Pharmaceutical Holdings Co., Ltd.).
  • Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments. 

Retinal Disorder Treatment Market - Scope of the Report

TMR’s report on the global retinal disorder treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators for the market during the forecast period from 2019 to 2027. The report provides revenue of the retinal disorder treatment market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the retinal disorder treatment market from 2019 to 2027.

The report is prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Extensive secondary research involved reaching out to key players’ product literature, annual reports, press releases, and relevant documents to understand the retinal disorder treatment market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the retinal disorder treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Moreover, the report sheds light on changing competitive dynamics in the retinal disorder treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the retinal disorder treatment market.

The report delves into the competitive landscape of the retinal disorder treatment market. Key players operating in the retinal disorder treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the retinal disorder treatment market that are profiled in this report.

Key Questions Answered in TMR’s Report on Retinal Disorder Treatment Market

  • What is the sales/revenue generated by retinal disorder treatment products across all regions during the forecast period?
  • What are the opportunities in the retinal disorder treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • In which region is the retinal disorder treatment market set to expand at the fastest CAGR during the forecast period?
  • Which product segment is expected to generate the highest revenue globally in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Retinal Disorder Treatment Market - Research Objectives and Research Approach

The comprehensive report on the retinal disorder treatment market begins with an overview, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the retinal disorder treatment market, in terms of disease indication, therapeutic class, dosage form, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2027 has also been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the retinal disorder treatment market.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Retinal Disorder Treatment Market - Segmentation

TMR’s study on the retinal disorder treatment market includes information divided into four segments: disease indication, therapeutic class, dosage form, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the retinal disorder treatment market have been discussed in detail.

Disease Indication

Macular Degeneration

Diabetic Retinopathy

Diabetic Macular Edema

Others (Retinal Vein Occlusion, etc.)

Therapeutic Class

Anti-VEGF Agents

Others (Anti-inflammatory Drugs, etc.)

Dosage Form

Gels

Eye Solutions

Capsules & Tablets

Eye Drops

Ointments

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Sales

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface 

    1.1. Report Scope and Market Segmentation 

    1.2. Research Highlights

2. Assumptions and Research Methodology 

    2.1. Assumptions

    2.2. Research Methodology

3. Executive Summary

    3.1. Global Retinal Disorder Treatment Market Snapshot

4. Market Overview

    4.1. Product Overview

    4.2. Key Industry Events

    4.3. Market Dynamics

        4.3.1. Drivers and Restraints Snapshot Analysis

        4.3.2. Drivers

        4.3.3. Restraints 

        4.3.4. Opportunities 

    4.4. Global Retinal Disorder Treatment Market Revenue Projection

    4.5. Global Retinal Disorder Treatment Market Outlook

5. Market Outlook

    5.1. Clinical Trial Analysis

    5.2. Regulatory Scenario

    5.3. Pipeline Analysis

    5.4. Key Mergers & Acquisitions

    5.5. Reimbursement Scenario

6. Global Retinal Disorder Treatment Market Analysis, by Disease Indication

    6.1. Introduction 

    6.2. Global Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Disease Indication

    6.3. Global Retinal Disorder Treatment Market Forecast, by Disease Indication

        6.3.1. Macular Degeneration

            6.3.1.1. Dry Macular Degeneration

            6.3.1.2. Wet Macular Degeneration

        6.3.2. Diabetic Retinopathy

        6.3.3. Diabetic Macular Edema

        6.3.4. Others (Retinal Vein Occlusion, etc.)

7. Global Retinal Disorder Treatment Market Analysis, by Therapeutic Class

    7.1. Introduction 

    7.2. North America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Therapeutic Class

    7.3. North America Retinal Disorder Treatment Market Forecast, by Therapeutic Class

        7.3.1. Anti-VEGF Agents

        7.3.2. Others (Anti-inflammatory Drugs, etc.)

8. Global Retinal Disorder Treatment Market Analysis, by Dosage Form 

    8.1. Introduction 

    8.2. Global Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Dosage Form

    8.3. Global Retinal Disorder Treatment Market Forecast, by Dosage Form

        8.3.1. Gels

        8.3.2. Eye Solutions

        8.3.3. Capsules & Tablets

        8.3.4. Eye Drops

        8.3.5. Ointments

    8.4. Global Retinal Disorder Treatment Market Analysis, by Dosage Form

9. Global Retinal Disorder Treatment Market Analysis, by Distribution Channel

    9.1. Introduction 

    9.2. Global Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    9.3. Global Retinal Disorder Treatment Market Forecast, by Distribution Channel

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Sales

    9.4. Global Retinal Disorder Treatment Market Analysis, by Distribution Channel

10. Global Retinal Disorder Treatment Market Analysis, by Region

    10.1. Global Retinal Disorder Treatment Market Scenario, by Country

    10.2. Global Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Region

    10.3. Global Retinal Disorder Treatment Market Forecast, by Region

        10.3.1. North America

        10.3.2. Europe

        10.3.3. Asia Pacific

        10.3.4. Latin America

        10.3.5. Middle East & Africa

11. North America Retinal Disorder Treatment Market Analysis

    11.1. Key Findings

    11.2. North America Retinal Disorder Treatment Market Overview

    11.3. North America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Country

    11.4. North America Retinal Disorder Treatment Market Forecast, by Country

        11.4.1. U.S.

        11.4.2. Canada

    11.5. North America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Disease Indication

    11.6. North America Retinal Disorder Treatment Market Forecast, by Disease Indication

        11.6.1. Macular Degeneration

            11.6.1.1. Dry Macular Degeneration

            11.6.1.2. Wet Macular Degeneration

        11.6.2. Diabetic Retinopathy

        11.6.3. Diabetic Macular Edema

        11.6.4. Others (Retinal Vein Occlusion, etc.)

    11.7. North America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Therapeutic Class

    11.8. North America Retinal Disorder Treatment Market Forecast, by Therapeutic Class

        11.8.1. Anti-VEGF Agents

        11.8.2. Others (Anti-inflammatory Drugs, etc.)

    11.9. North America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Dosage Form

    11.10. North America Retinal Disorder Treatment Market Forecast, by Dosage Form

        11.10.1. Gels

        11.10.2. Eye Solutions

        11.10.3. Capsules & Tablets

        11.10.4. Eye Drops

        11.10.5. Ointments

    11.11. North America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    11.12. North America Retinal Disorder Treatment Market Forecast, by Distribution Channel

        11.12.1. Hospital Pharmacies

        11.12.2. Retail Pharmacies

        11.12.3. Online Sales

12. Europe  Retinal Disorder Treatment Market Analysis

    12.1. Key Findings

    12.2. Europe Retinal Disorder Treatment Market Overview

    12.3. Europe Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

    12.4. Europe Retinal Disorder Treatment Market Forecast, by Country/Sub-region

        12.4.1. Germany

        12.4.2. France

        12.4.3. U.K.

        12.4.4. Italy

        12.4.5. Spain

        12.4.6. Rest of Europe

    12.5. Europe Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Disease Indication

    12.6. Europe Retinal Disorder Treatment Market Forecast, by Disease Indication

        12.6.1. Macular Degeneration

            12.6.1.1. Dry Macular Degeneration

            12.6.1.2. Wet Macular Degeneration

        12.6.2. Diabetic Retinopathy

        12.6.3. Diabetic Macular Edema

        12.6.4. Others (Retinal Vein Occlusion, etc.)

    12.7. Europe Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Therapeutic Class

    12.8. Europe Retinal Disorder Treatment Market Forecast, by Therapeutic Class

        12.8.1. Anti-VEGF Agents

        12.8.2. Others (Anti-inflammatory Drugs, etc.)

    12.9. Europe Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Dosage Form

    12.10. Europe Retinal Disorder Treatment Market Forecast, by Dosage Form

        12.10.1. Gels

        12.10.2. Eye Solutions

        12.10.3. Capsules & Tablets

        12.10.4. Eye Drops

        12.10.5. Ointments

    12.11. Europe Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    12.12. Europe Retinal Disorder Treatment Market Forecast, by Distribution Channel

        12.12.1. Hospital Pharmacies

        12.12.2. Retail Pharmacies

        12.12.3. Online Sales

13. Asia Pacific Retinal Disorder Treatment Market Analysis

    13.1. Key Findings

    13.2. Asia Pacific Retinal Disorder Treatment Market Overview

    13.3. Asia Pacific Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

    13.4. Asia  Pacific Retinal Disorder Treatment Market Forecast, by Country/Sub-region

        13.4.1. Japan

        13.4.2. China

        13.4.3. India

        13.4.4. Australia & New Zealand

        13.4.5. Rest of Asia Pacific

    13.5. Asia Pacific Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Disease Indication

    13.6. Asia Pacific Retinal Disorder Treatment Market Forecast, by Disease Indication

        13.6.1. Macular Degeneration

            13.6.1.1. Dry Macular Degeneration

            13.6.1.2. Wet Macular Degeneration

        13.6.2. Diabetic Retinopathy

        13.6.3. Diabetic Macular Edema

        13.6.4. Others (Retinal Vein Occlusion, etc.)

    13.7. Asia Pacific Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Therapeutic Class

    13.8. Asia Pacific Retinal Disorder Treatment Market Forecast, by Therapeutic Class

        13.8.1. Anti-VEGF Agents

        13.8.2. Others (Anti-inflammatory Drugs, etc.)

    13.9. Asia  Pacific Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Dosage Form

    13.10. Asia  Pacific Retinal Disorder Treatment Market Forecast, by Dosage Form

        13.10.1. Gels

        13.10.2. Eye Solutions

        13.10.3. Capsules & Tablets

        13.10.4. Eye Drops

        13.10.5. Ointments

    13.11. Asia  Pacific Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    13.12. Asia  Pacific Retinal Disorder Treatment Market Forecast, by Distribution Channel

        13.12.1. Hospital Pharmacies

        13.12.2. Retail Pharmacies

        13.12.3. Online Sales

14. Latin America Retinal Disorder Treatment Market Analysis

    14.1. Key Findings

    14.2. Latin America Retinal Disorder Treatment Market Overview

    14.3. Latin America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

    14.4. Latin America  Retinal Disorder Treatment Market Forecast, by Country/Sub-region

        14.4.1. Brazil

        14.4.2. Mexico

        14.4.3. Rest of Latin America

    14.5. Latin America  Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Disease Indication

    14.6. Latin America  Retinal Disorder Treatment Market Forecast, by Disease Indication

        14.6.1. Macular Degeneration

            14.6.1.1. Dry Macular Degeneration

            14.6.1.2. Wet Macular Degeneration

        14.6.2. Diabetic Retinopathy

        14.6.3. Diabetic Macular Edema

        14.6.4. Others (Retinal Vein Occlusion, etc.)

    14.7. Latin America  Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Therapeutic Class

    14.8. Latin America  Retinal Disorder Treatment Market Forecast, by Therapeutic Class

        14.8.1. Anti-VEGF Agents

        14.8.2. Others (Anti-inflammatory Drugs, etc.)

    14.9. Latin America  Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Dosage Form

    14.10. Latin America  Retinal Disorder Treatment Market Forecast, by Dosage Form

        14.10.1. Gels

        14.10.2. Eye Solutions

        14.10.3. Capsules & Tablets

        14.10.4. Eye Drops

        14.10.5. Ointments

    14.11. Latin America  Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    14.12. Latin America  Retinal Disorder Treatment Market Forecast, by Distribution Channel

        14.12.1. Hospital Pharmacies

        14.12.2. Retail Pharmacies

        14.12.3. Online Sales

15. Middle East & Africa Retinal Disorder Treatment Market Analysis

    15.1. Key Findings

    15.2. Middle East & Africa  Retinal Disorder Treatment Market Overview

    15.3. Middle East & Africa  Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

    15.4. Middle East & Africa  Retinal Disorder Treatment Market Forecast, by Country/Sub-region

        15.4.1. GCC Countries

        15.4.2. South Africa

        15.4.3. Rest of Middle East & Africa 

    15.5. Middle East & Africa Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Disease Indication

    15.6. Middle East & Africa  Retinal Disorder Treatment Market Forecast, by Disease Indication

        15.6.1. Macular Degeneration

            15.6.1.1. Dry Macular Degeneration

            15.6.1.2. Wet Macular Degeneration

        15.6.2. Diabetic Retinopathy

        15.6.3. Diabetic Macular Edema

        15.6.4. Others (Retinal Vein Occlusion, etc.)

    15.7. Middle East & Africa  Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Therapeutic Class

    15.8. Middle East & Africa  Retinal Disorder Treatment Market Forecast, by Therapeutic Class

        15.8.1. Anti-VEGF Agents

        15.8.2. Others (Anti-inflammatory Drugs, etc.)

    15.9. Middle East & Africa  Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Dosage Form

    15.10. Middle East & Africa  Retinal Disorder Treatment Market Forecast, by Dosage Form

        15.10.1. Gels

        15.10.2. Eye Solutions

        15.10.3. Capsules & Tablets

        15.10.4. Eye Drops

        15.10.5. Ointments

    15.11. Middle East & Africa  Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    15.12. Middle East & Africa  Retinal Disorder Treatment Market Forecast, by Distribution Channel

        15.12.1. Hospital Pharmacies

        15.12.2. Retail Pharmacies

        15.12.3. Online Sales

16. Competition Analysis

    16.1. Global Retinal Disorder Treatment Market Share Analysis, by Company

    16.2. Competition Matrix

    16.3. Company Profile

        16.3.1. Santen Pharmaceutical Co., Ltd. 

            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.1.2. Financial Overview

            16.3.1.3. Product Portfolio

            16.3.1.4. SWOT Analysis

            16.3.1.5. Strategic Overview

        16.3.2. Regeneron Pharmaceuticals, Inc. 

            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.2.2. Financial Overview

            16.3.2.3. Product Portfolio

            16.3.2.4. SWOT Analysis

            16.3.2.5. Strategic Overview

        16.3.3. F. Hoffmann-La Roche Ltd. 

            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.3.2. Financial Overview

            16.3.3.3. Product Portfolio

            16.3.3.4. SWOT Analysis

            16.3.3.5. Strategic Overview

        16.3.4. Pfizer, Inc. 

            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.4.2. Financial Overview

            16.3.4.3. Product Portfolio

            16.3.4.4. SWOT Analysis

            16.3.4.5. Strategic Overview

        16.3.5. Allergan plc

            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.5.2. Financial Overview

            16.3.5.3. Product Portfolio

            16.3.5.4. SWOT Analysis

            16.3.5.5. Strategic Overview

        16.3.6. Shire (Takeda Pharmaceutical Company Limited) 

            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.6.2. Financial Overview

            16.3.6.3. Product Portfolio

            16.3.6.4. SWOT Analysis

            16.3.6.5. Strategic Overview

        16.3.7. Bayer AG 

            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.7.2. Financial Overview

            16.3.7.3. Product Portfolio

            16.3.7.4. SWOT Analysis

            16.3.7.5. Strategic Overview

        16.3.8. Graybug Vision, Inc. 

            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.8.2. Financial Overview

            16.3.8.3. Product Portfolio

            16.3.8.4. SWOT Analysis

            16.3.8.5. Strategic Overview

        16.3.9. Novartis AG

            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.9.2. Financial Overview

            16.3.9.3. Product Portfolio

            16.3.9.4. SWOT Analysis

            16.3.9.5. Strategic Overview

        16.3.10. Acucela Inc. (Kubota Pharmaceutical Holdings Co., Ltd.) 

            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.10.2. Financial Overview

            16.3.10.3. Product Portfolio

            16.3.10.4. SWOT Analysis

            16.3.10.5. Strategic Overview

List of Tables

Table 01: Global Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 02: Global Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Macular Degeneration, 2017–2027

Table 03: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027

Table 04: Global Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 05: Global Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 06: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 07: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 08: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Macular Degeneration, 2017–2027

Table 09: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027

Table 10: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027

Table 11: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 12: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 13: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 14: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Macular Degeneration, 2017–2027

Table 15: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027

Table 16: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027

Table 17: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 18: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 19: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 20: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Macular Degeneration, 2017–2027

Table 21: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027

Table 22: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027

Table 23: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 24: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 25: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 26: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Macular Degeneration, 2017–2027

Table 27: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027

Table 28: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027

Table 29: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 30: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 31: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 32: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Macular Degeneration, 2017–2027

Table 33: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027

Table 34: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027

Table 35: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

List of Figures

Figure 01: Global retinal disorder treatment Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027

Figure 02: Global Retinal Disorder Treatment Market Value (US$ Mn) and Forecast, 2019–2027

Figure 03: Global Retinal Disorder Treatment Market Value Share (%), by Disease Indication, 2018

Figure 04: Global Retinal Disorder Treatment Market Value Share (%), by Therapeutic Class, 2018

Figure 05: Global Retinal Disorder Treatment Market Value Share (%), by Dosage Form, 2018

Figure 06: Global Retinal Disorder Treatment Market Value Share (%), by Region, 2018

Figure 07: Global Retinal Disorder Treatment Market Value Share (%), by Distribution Channel, 2018

Figure 08: Clinical Trial Analysis by Phase

Figure 09: Clinical Trial Analysis by Status

Figure 10: Clinical Trial Analysis by Completion and Termination Rate

Figure 11: Clinical Trial Analysis by Region

Figure 12: Global Retinal Disorder Treatment Market Value Share Analysis, by Disease Indication, 2018 and 2027

Figure 13: Global Retinal Disorder Treatment Market Attractiveness, by Disease Indication, 2019–2027

Figure 14: Global Retinal Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Macular Degeneration, 2017–2027

Figure 15: Global Retinal Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Diabetes Retinopathy, 2017–2027

Figure 16: Global Retinal Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Diabetic Macular Edema, 2017–2027

Figure 17: Global Retinal Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others (Retinal Vein Occlusion, etc.), 2017–2027

Figure 18: North America Retinal Disorder Treatment Market Value Share Analysis, by Therapeutic Class, 2018 and 2027

Figure 19: North America Retinal Disorder Treatment Market Attractiveness, by Therapeutic Class, 2019–2027

Figure 20: Global Retinal Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anti-VEGF Agents, 2017–2027

Figure 21: Global Retinal Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others (Anti-inflammatory Drugs, etc.), 2017–2027

Figure 22: Global Retinal Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Gels, 2017–2027

Figure 23: Global Retinal Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Eye Solutions, 2017–2027

Figure 24: Global Retinal Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Capsules & Tablets, 2017–2027

Figure 25: Global Retinal Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Eye Drops, 2017–2027

Figure 26: Global Retinal Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Ointments, 2017–2027

Figure 27: Global Retinal Disorder Treatment Market Value Share, by Distribution Channel, 2018 and 2027

Figure 28: Global Retinal Disorder Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 29: Global Retinal Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027

Figure 30: Global Retinal Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027

Figure 31: Global Retinal Disorder Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Sales, 2017–2027

Figure 32: Global Retinal Disorder Treatment Market Value Share, by Region, 2018 and 2027 

Figure 33: Global Retinal Disorder Treatment Market Attractiveness, by Region, 2019–2027

Figure 34: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 35: North America Retinal Disorder Treatment Market Value Share Analysis, by Country, 2018 and 2027

Figure 36: North America Retinal Disorder Treatment Market Attractiveness, by Country, 2019–2027

Figure 37: North America Retinal Disorder Treatment Market Value Share Analysis, by Disease Indication, 2018 and 2027

Figure 38: North America Retinal Disorder Treatment Market Attractiveness, by Disease Indication, 2019–2027

Figure 39: North America Retinal Disorder Treatment Market Value Share Analysis, by Therapeutic Class, 2018 and 2027

Figure 40: North America Retinal Disorder Treatment Market Attractiveness, by Therapeutic Class, 2019–2027

Figure 41: North America Retinal Disorder Treatment Market Value Share, by Dosage Form, 2018 and 2027

Figure 42: North America Retinal Disorder Treatment Market Attractiveness, by Dosage Form, 2019–2027

Figure 43: North America Retinal Disorder Treatment Market Value Share, by Distribution Channel, 2018 and 2027

Figure 44: North America Retinal Disorder Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 45: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 46: Europe Retinal Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 47: Europe Retinal Disorder Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 48: Europe Retinal Disorder Treatment Market Value Share Analysis, by Disease Indication, 2018 and 2027

Figure 49: Europe Retinal Disorder Treatment Market Attractiveness, by Disease Indication, 2019–2027

Figure 50: Europe Retinal Disorder Treatment Market Value Share Analysis, by Therapeutic Class, 2018 and 2027

Figure 51: Europe Retinal Disorder Treatment Market Attractiveness, by Therapeutic Class, 2019–2027

Figure 52: Europe Retinal Disorder Treatment Market Value Share, by Dosage Form, 2018 and 2027

Figure 53: Europe Retinal Disorder Treatment Market Attractiveness, by Dosage Form, 2019–2027

Figure 54: Europe Retinal Disorder Treatment Market Value Share, by Distribution Channel, 2018 and 2027

Figure 55: Europe Retinal Disorder Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 56: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 57: Asia Pacific Retinal Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 58: Asia Pacific Retinal Disorder Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 59: Asia Pacific Retinal Disorder Treatment Market Value Share Analysis, by Disease Indication, 2018 and 2027

Figure 60: Asia Pacific Retinal Disorder Treatment Market Attractiveness, by Disease Indication, 2019–2027

Figure 61: Asia Pacific Retinal Disorder Treatment Market Value Share Analysis, by Therapeutic Class, 2018 and 2027

Figure 62: Asia Pacific Retinal Disorder Treatment Market Attractiveness, by Therapeutic Class, 2019–2027

Figure 63: Asia Pacific Retinal Disorder Treatment Market Value Share, by Dosage Form, 2018 and 2027

Figure 64: Asia Pacific Retinal Disorder Treatment Market Attractiveness, by Dosage Form, 2019–2027

Figure 65: Asia Pacific Retinal Disorder Treatment Market Value Share, by Distribution Channel, 2018 and 2027

Figure 66: Asia Pacific Retinal Disorder Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 67: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 68: Latin America Retinal Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 69: Latin America Retinal Disorder Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 70: Latin America Retinal Disorder Treatment Market Value Share Analysis, by Disease Indication, 2018 and 2027

Figure 71: Latin America Retinal Disorder Treatment Market Attractiveness, by Disease Indication, 2019–2027

Figure 72: Latin America Retinal Disorder Treatment Market Value Share Analysis, by Therapeutic Class, 2018 and 2027

Figure 73: Latin America Retinal Disorder Treatment Market Attractiveness, by Therapeutic Class, 2019–2027

Figure 74: Latin America Retinal Disorder Treatment Market Value Share, by Dosage Form, 2018 and 2027

Figure 75: Latin America Retinal Disorder Treatment Market Attractiveness, by Dosage Form, 2019–2027

Figure 76: Latin America Retinal Disorder Treatment Market Value Share, by Distribution Channel, 2018 and 2027

Figure 77: Latin America Retinal Disorder Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 78: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 79: Middle East & Africa Retinal Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 80: Middle East & Africa Retinal Disorder Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 81: Middle East & Africa Retinal Disorder Treatment Market Value Share Analysis, by Disease Indication, 2018 and 2027

Figure 82: Middle East & Africa Retinal Disorder Treatment Market Attractiveness, by Disease Indication, 2019–2027

Figure 83: Middle East & Africa Retinal Disorder Treatment Market Value Share Analysis, by Therapeutic Class, 2018 and 2027

Figure 84: Middle East & Africa Retinal Disorder Treatment Market Attractiveness, by Therapeutic Class, 2019–2027

Figure 85: Middle East & Africa Retinal Disorder Treatment Market Value Share, by Dosage Form, 2018 and 2027

Figure 86: Middle East & Africa Retinal Disorder Treatment Market Attractiveness, by Dosage Form, 2019–2027

Figure 87: Middle East & Africa Retinal Disorder Treatment Market Value Share, by Distribution Channel, 2018 and 2027

Figure 88: Middle East & Africa Retinal Disorder Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Retinal Disorder Treatment Market